JPS61165322A - スパガリン類の注射用凍結乾燥製剤 - Google Patents

スパガリン類の注射用凍結乾燥製剤

Info

Publication number
JPS61165322A
JPS61165322A JP60003351A JP335185A JPS61165322A JP S61165322 A JPS61165322 A JP S61165322A JP 60003351 A JP60003351 A JP 60003351A JP 335185 A JP335185 A JP 335185A JP S61165322 A JPS61165322 A JP S61165322A
Authority
JP
Japan
Prior art keywords
injection
freeze
spergualin
formula
spagarin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP60003351A
Other languages
English (en)
Japanese (ja)
Other versions
JPH0413325B2 (https=
Inventor
Hamao Umezawa
梅沢　浜夫
Shintaro Suzuki
信太郎 鈴木
Takaaki Okuma
大熊　高明
Fumihiro Sato
文弘 佐藤
Teruya Nakamura
中村　輝也
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Microbial Chemistry Research Foundation
Original Assignee
Microbial Chemistry Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Microbial Chemistry Research Foundation filed Critical Microbial Chemistry Research Foundation
Priority to JP60003351A priority Critical patent/JPS61165322A/ja
Priority to EP85116670A priority patent/EP0188821B1/en
Priority to DE8585116670T priority patent/DE3579146D1/de
Priority to AT85116670T priority patent/ATE55246T1/de
Priority to US06/817,266 priority patent/US4710517A/en
Priority to KR1019860000125A priority patent/KR920003331B1/ko
Priority to CA000499451A priority patent/CA1263316A/en
Priority to AU52224/86A priority patent/AU589939B2/en
Priority to IE8986A priority patent/IE58220B1/en
Priority to CN86100157A priority patent/CN1010279B/zh
Publication of JPS61165322A publication Critical patent/JPS61165322A/ja
Priority to US07/084,167 priority patent/US4876244A/en
Publication of JPH0413325B2 publication Critical patent/JPH0413325B2/ja
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
JP60003351A 1985-01-14 1985-01-14 スパガリン類の注射用凍結乾燥製剤 Granted JPS61165322A (ja)

Priority Applications (11)

Application Number Priority Date Filing Date Title
JP60003351A JPS61165322A (ja) 1985-01-14 1985-01-14 スパガリン類の注射用凍結乾燥製剤
EP85116670A EP0188821B1 (en) 1985-01-14 1985-12-31 Stabilized spergualin-containing pharmaceutical compositions having cancer controlling and immunomodulating activity
DE8585116670T DE3579146D1 (de) 1985-01-14 1985-12-31 Stabilisierte spergualin enthaltende arzneimittel mit krebshemmender und immunomodulierender wirkung.
AT85116670T ATE55246T1 (de) 1985-01-14 1985-12-31 Stabilisierte spergualin enthaltende arzneimittel mit krebshemmender und immunomodulierender wirkung.
US06/817,266 US4710517A (en) 1985-01-14 1986-01-09 Medical composition for injection containing a spergualin as active ingredient and process for preparing the same
KR1019860000125A KR920003331B1 (ko) 1985-01-14 1986-01-11 활성성분으로 스페르구알린(Spergualin)을 함유하는 주사제 조성물과 그 제조방법.
CA000499451A CA1263316A (en) 1985-01-14 1986-01-13 Medical composition for injection containing a spergualin as active ingredient and process for preparing the same
AU52224/86A AU589939B2 (en) 1985-01-14 1986-01-13 Medical composition for injection containing a spergualin as active ingredient and process for preparing the same
IE8986A IE58220B1 (en) 1985-01-14 1986-01-13 Stabilized spergualin-containing pharmaceutical compositions having cancer controlling and immunomodulating activity
CN86100157A CN1010279B (zh) 1985-01-14 1986-01-13 含有斯波胍灵活性成分的注射用药物组合物的制备方法
US07/084,167 US4876244A (en) 1985-01-14 1987-08-11 Medical composition for injection containing a spergualin as active ingredient and process for preparing the same

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP60003351A JPS61165322A (ja) 1985-01-14 1985-01-14 スパガリン類の注射用凍結乾燥製剤

Publications (2)

Publication Number Publication Date
JPS61165322A true JPS61165322A (ja) 1986-07-26
JPH0413325B2 JPH0413325B2 (https=) 1992-03-09

Family

ID=11554927

Family Applications (1)

Application Number Title Priority Date Filing Date
JP60003351A Granted JPS61165322A (ja) 1985-01-14 1985-01-14 スパガリン類の注射用凍結乾燥製剤

Country Status (10)

Country Link
US (2) US4710517A (https=)
EP (1) EP0188821B1 (https=)
JP (1) JPS61165322A (https=)
KR (1) KR920003331B1 (https=)
CN (1) CN1010279B (https=)
AT (1) ATE55246T1 (https=)
AU (1) AU589939B2 (https=)
CA (1) CA1263316A (https=)
DE (1) DE3579146D1 (https=)
IE (1) IE58220B1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003504323A (ja) * 1999-07-13 2003-02-04 ファルマソル ゲーエムベーハー 超微細マイクロ粒子およびナノ粒子の制御された製造方法。
JPWO2003007967A1 (ja) * 2001-07-17 2004-11-04 塩野義製薬株式会社 注射用医薬製剤

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61129119A (ja) * 1984-11-13 1986-06-17 Microbial Chem Res Found 新規免疫抑制剤
EP0241797B1 (en) * 1986-04-04 1991-06-12 Microbial Chemistry Research Foundation Novel spergualin-related compounds and process for producing the same
CA1330650C (fr) * 1987-10-22 1994-07-12 Alain Huc Procede de stabilisation de phases lamellaires lipidiques hydratees, par exemple de liposomes, composition de phases lamellaires lipidiques hydratees, par exemple des liposomes, stabilisees par un emploi d'un support stabilisant a base d'atelocollagene et de glycosaminoglycannes, et utilisation en pharmacie ou en ...
FR2622104B1 (fr) * 1987-10-22 1990-03-30 Bioetica Sa Procede de stabilisation de phases lamellaires lipidiques hydratees, par ex. de liposomes, composition de phases lamellaires lipidiques hydratees, par ex. des liposomes, stabilisees par un emploi d'un support stabilisant a base d'atelocollagene et de glycosaminoglycannes et utilisation en pharmacie ou en cosmetologie
KR900700114A (ko) * 1988-01-19 1990-08-11 모세 쥬다 포크만 성장억제 작용제 및 그 사용법
US5760015A (en) * 1988-01-19 1998-06-02 The Trustees Of The University Of Pennsylvania Cyclodextrin compounds and methods of making and use thereof
US5019562A (en) * 1988-01-19 1991-05-28 The Trustees Of The University Of Pennsylvania/Childrens Hospital Corporation Growth inhibiting agent and the use thereof
US5637575A (en) * 1988-01-19 1997-06-10 The Trustees Of The University Of Pennsylvania Methods of inhibiting restenosis
US5658894A (en) * 1989-04-23 1997-08-19 The Trustees Of The University Of Pennsylvania Compositions for inhibiting restenosis
AU626538B2 (en) * 1988-01-19 1992-08-06 Moses Judah Folkman Growth inhibiting agent and the use thereof
US5002756A (en) * 1988-04-04 1991-03-26 Zaidanhojin Biseibutsu Kagakukenkyukai Method for relieving radiogenic or drug-induced side effects
DK0397542T3 (da) * 1988-12-02 1992-12-07 Coletica Stabiliseringsfremgangsmåde for hydratiserede lamellare faser
JPH03505334A (ja) * 1989-04-11 1991-11-21 イミユノバイオロジー・リサーチ・インスチチユート・インコーポレーテツド 凍結乾燥されたペプチド製剤
US5441944A (en) * 1989-04-23 1995-08-15 The Trustees Of The University Of Pennsylvania Substituted cyclodextrin sulfates and their uses as growth modulating agents
US5446030A (en) * 1991-09-19 1995-08-29 Weisz; Paul B. Prevention of hemolysis
US5424301A (en) * 1993-02-01 1995-06-13 Warner-Lambert Company Starch stabilized o-substituted tetrahydropyridine oxime cholinergic agents
JPH08511041A (ja) * 1993-03-31 1996-11-19 ザ トラスティーズ オブ ザ ユニバーシティー オブ ペンシルバニア 哺乳動物生組織の増殖に作用する方法、及びそのための化合物ならびに組成物
US5505715A (en) * 1994-02-25 1996-04-09 Bristol-Myers Squibb Company Iontophoretic transdermal delivery of deoxyspergualin compounds
CA2183917A1 (en) * 1995-09-26 1997-03-27 Xuebao Wang Preparation of optically active (s)-(-) and (r)-(+)- deoxyspergualin and novel intermediates thereof
ES2243994T5 (es) 1996-04-19 2009-10-29 Grifols Inc. Procedimiento para la inactivacion virica de proteinas de la sangre liofilizadas.
US6133248A (en) * 1997-06-13 2000-10-17 Cydex, Inc. Polar drug of prodrug compositions with extended shelf-life storage and a method of making thereof
AU2001271037A1 (en) * 2000-07-13 2002-01-30 Daiichi Pharmaceutical Co., Ltd. Pharmaceutical compositions containing dds compounds
US20020146409A1 (en) * 2001-01-30 2002-10-10 Herring Steven W. Methods for stabilizing lyophilized blood proteins

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54157818A (en) * 1978-06-02 1979-12-13 Tokyo Tanabe Co Injectionable preparation of chlorethylnitrosourea compound

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5748957A (en) * 1980-09-08 1982-03-20 Microbial Chem Res Found Novel antibiotic bmg 162-af2, its preparation and carcinostatic agent comprising it as active ingredient
JPS57185254A (en) * 1981-05-11 1982-11-15 Microbial Chem Res Found Novel carcinostatic substances and their preparation
JPS5862152A (ja) * 1981-10-08 1983-04-13 Microbial Chem Res Found Ｎ−〔４−（３−アミノプロピル）アミノブチル〕−２−（ω−グアニジノ脂肪酸アミド）−２−ヒドロキシエタンアミドおよびその誘導体ならびにその製造法
JPS58198455A (ja) * 1982-05-17 1983-11-18 Microbial Chem Res Found （−）−１５−デオキシスパガリンおよびその製造法並びにその中間体
JPS5942356A (ja) * 1982-09-02 1984-03-08 Microbial Chem Res Found スパガリン関連化合物およびその製造法
US4525299A (en) * 1983-05-10 1985-06-25 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai (-)-15-Deoxyspergualin, process for the preparation thereof, and intermediate of the same
JPS60185758A (ja) * 1984-03-02 1985-09-21 Microbial Chem Res Found フエニレン基を有するスパガリン関連化合物およびその製造法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54157818A (en) * 1978-06-02 1979-12-13 Tokyo Tanabe Co Injectionable preparation of chlorethylnitrosourea compound

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003504323A (ja) * 1999-07-13 2003-02-04 ファルマソル ゲーエムベーハー 超微細マイクロ粒子およびナノ粒子の制御された製造方法。
JPWO2003007967A1 (ja) * 2001-07-17 2004-11-04 塩野義製薬株式会社 注射用医薬製剤
US7645793B2 (en) 2001-07-17 2010-01-12 Shionogi & Co., Ltd. Injectable pharmaceutical formulations

Also Published As

Publication number Publication date
EP0188821B1 (en) 1990-08-08
US4710517A (en) 1987-12-01
EP0188821A3 (en) 1987-08-12
CN86100157A (zh) 1986-08-27
CA1263316A (en) 1989-11-28
ATE55246T1 (de) 1990-08-15
IE860089L (en) 1986-07-14
KR860005636A (ko) 1986-08-11
AU5222486A (en) 1986-07-17
DE3579146D1 (de) 1990-09-13
KR920003331B1 (ko) 1992-04-27
CN1010279B (zh) 1990-11-07
US4876244A (en) 1989-10-24
IE58220B1 (en) 1993-08-11
JPH0413325B2 (https=) 1992-03-09
AU589939B2 (en) 1989-10-26
EP0188821A2 (en) 1986-07-30

Similar Documents

Publication Publication Date Title
JPS61165322A (ja) スパガリン類の注射用凍結乾燥製剤
DE60132108T2 (de) Gefriergetrocknetes pantoprazol-präparat und pantoprazol-injektion
AU655935B2 (en) Pharmaceutical composition of florfenicol
EA002776B1 (ru) Фармацевтические композиции, содержащие циклодекстрины и таксоиды
JP6908448B2 (ja) 医薬組成物
FI86690B (fi) Foerfarande foer framstaellning av oxazafosforinloesningar.
KR20000049125A (ko) 외용 국소 마취제
FI86800C (fi) Menetelmä injektoitavan, käyttövalmiin, steriilin, pyrogeenivapaan antrasykliiniglykosidiliuoksen valmistamiseksi
WO2005004874A1 (en) Stable tetrodotoxin freeze drying medicinal preparation
KR101468153B1 (ko) 5α-안드로스테인-3β,5,6β-트리올 주사제 및 제조방법
CA1249223A (en) Solid drug formulations and stable suspensions
SU978715A3 (ru) Способ получени водного раствора простациклина или его соли
CN100376251C (zh) 含有甲基维生素b12的冻干制剂及其制备方法
FI90824B (fi) Menetelmä kylmäkuivattujen farmaseuttisten fenyylikinoliinikarboksyylihappokoostumusten valmistamiseksi
HU179989B (en) Process for preparing pharmacological compositions containing r-/+/-1-/1-phenyl-ethyl/-1h-imidazol-5-carboxylic acid ethyl ester for intravenous administration
KR20240121186A (ko) 주사용 조성물, 이를 포함하는 약학적 제제 및 이의 제조 방법
RS49608B (sr) Stabilizovane farmaceutske smeše na bazi hinupristina i dalfopristina i njihovo dobivanje
CN103040737B (zh) 一种含有兰索拉唑化合物的药物组合物及其制备方法
JPS59216818A (ja) 経皮吸収外用製剤
WO2003099288A1 (en) Medicinal composition
KR102807088B1 (ko) 안정화된 펩타이드 액상 조성물
US4416874A (en) Injectable compositions of BBM-928A
JPS6165819A (ja) 有機ゲルマニウム化合物を含有する薬剤組成物
KR100219439B1 (ko) 녹용 캅셀제
WO2023209731A1 (en) Injectable liquid or lyophilized powder dosage forms of selexipag and their method of preparation

Legal Events

Date Code Title Description
R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term